Discussion about this post

User's avatar
Quinney's avatar

I think patients should have equal control with Healthcare Providers. I believe that HSCT is more effective and cheaper for people with MS. I agree with msintheus that with the limitations of Ocrelizumab regarding vaccine antibodies, HSCT needs to be much more readily available both here in the UK and across the globe. HSCT has evolved and should now be considered a frontline treatment. Prof G, thanks for raising this important topic and also for admitting last week on twitter that your previous knowledge about HSCT abroad was out of date. This is so very rare for a Consultant to admit this. Thankyou from the bottom of my heart.

Expand full comment
msintheus's avatar

Given the new - very serious risks of being on Ocrelizumab (no response to covid jab, covid increases mortality) I think AHSCT should be standard offer for a lot more people now. The global dynamics and risks/benefits have changed substantially and treatment guidelines should adapt accordingly.

Expand full comment
47 more comments...

No posts